Big Pharma’s Aging Antibodies Cling To Their Crowns
Homegrown Stars, Canny Acquisitions And An Unexpected Treasure Hold Top Spots
Executive Summary
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?